Pancreatic Cancer Research

Clinical trialPhase 2Not yet recruiting

Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: An Open-Label, Single-Arm, Phase II Study

NCT07733050↗ ClinicalTrials.gov, retrieved 5 November 2026

Outcome
Ongoing
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Start
1 August 2026
Expected end
1 August 2028
Enrollment
34 participants
Sites
1
Primary outcomes
Overall Survival (OS)
Sponsor
Other
Results posted
No
Last update
29 July 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try